F2G is a biopharmaceutical company in the clinical stage, which is primarily engaged in the discovery and development of new treatments for severe invasive fungal infections. The company has pioneered a new class of antifungal agents, known as orotomides, which work differently from existing antifungal treatments. These agents target a specific enzyme, dihydroorotate dehydrogenase (DHODH), crucial in the fungal growth process.

The company's leading product, Olorofim, is currently in a Phase 2b open-label study. It has shown effectiveness against a wide range of mould infections, including rare and resistant strains that current treatments struggle to combat. Olorofim has received orphan drug status from both the European Medicines Agency and the FDA, indicating its potential to treat rare diseases.

F2G operates in the global antifungal market, which is worth over US$6 billion and growing annually due to an increase in the immune-compromised patient population. This growth is driven by increases in conditions like cancer and organ transplants, and the use of potent drugs, including broad-spectrum antibiotics, which can lead to fungal infections.

F2G's business model is based on the development and commercialization of its novel antifungal agents. The company generates revenue through the sales of its drugs once they have been approved by regulatory bodies.

F2G is headquartered in the UK and has subsidiaries in the US and Austria, indicating a global reach.

Keywords: Biopharmaceutical, Fungal Infections, Antifungal Agents, Orotomides, Olorofim, Clinical Stage, Orphan Drug Status, Global Market, Immune-Compromised Patients, Drug Development.